F3308-3604 | 91332-08-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: F3308-3604
• 英文别名: DL-α-Amino-γ-benzimidazolyl-(2)-buttersaeure；2-amino-4-(1H-benzoimidazol-2-yl)-butyric acid；2-amino-4-(1H-benzimidazol-2-yl)-butyric acid；2-Amino-4-(1H-benzimidazol-2-yl)-buttersaeure；2-azaniumyl-4-(1H-benzimidazol-2-yl)butanoate
• CAS: 91332-08-0
• 化学式: C₁₁H₁₃N₃O₂
• mdl: MFCD00447754
• 分子量: 219.243
• InChiKey: ULRAOHIYUQZJKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  92
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  ethyl-2-carbethoxy-2-acetylamino-2-cyanobutanoate 在 盐酸 、 乙醚 作用下， 生成 F3308-3604
  参考文献：
  名称：

  Behringer et al., Chemische Berichte, 1959, vol. 92, p. 910,913

  摘要：

  DOI：

文献信息

• [EN] SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS<br/>[FR] ANALOGUES DE POLYMYXINE DE REMPLACEMENT DE SÉRINE UTILES EN TANT QUE POTENTIALISATEURS D'ANTIBIOTIQUE
  申请人：SPERO OPCO

  公开号：WO2017189868A1

  公开（公告）日：2017-11-02

  The disclosure provides compounds of the formula I or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables R1 and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering a therapeutically effective amount of the antibacterial agent and a compound of formula I to a patient infected with the bacteria, simultaneously or sequentially.

  该披露提供了公式I或其互变异构体的化合物，或者是上述任一化合物的药用盐。变量R1和R2在披露中有定义。该披露还包括包括公式I化合物以及至少一种药用载体的药物组合物。该披露还包括一种使细菌对抗菌剂敏感的方法，包括向感染有该细菌的患者同时或顺序地给予抗菌剂和公式I化合物的治疗有效量。
• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• Verfahren zur Inhibierung der wasserstoffinduzierten Korrosion von metallischen Werkstoffen
  申请人：BAYER AG

  公开号：EP0226016A1

  公开（公告）日：1987-06-24

  Die wasserstoffinduzierte Korrosion von metallischen Werk­stoffen in Promotor-haltigem Wasser, Methanol oder deren Mischungen wird inhibiert durch Zugabe von 2-(ω-Amino­alkyl)-1,3-heterocyclen.

  通过添加 2-(ω-氨基烷基)-1,3-杂环，可抑制金属材料在含促进剂的水、甲醇或其混合物中因氢气引起的腐蚀。
• Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
  申请人：Friedrich-Alexander-Universität Erlangen-Nürnberg

  公开号：US10828281B2

  公开（公告）日：2020-11-10

  The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

  本发明涉及其化合物、同系物、立体异构体和化学修饰化合物，及其在预防和/或治疗肿瘤转移和/或软骨缺损中的用途，以及包含此类化合物的药物组合物。
• [EN] DIAGNOSTIC AND THERAPEUTIC AGENTS<br/>[FR] AGENTS DIAGNOSTIQUES ET THÉRAPEUTIQUES
  申请人：KARYON CTT LTD

  公开号：WO2007113385A1

  公开（公告）日：2007-10-11

  [EN] The present invention relates to tumor targeting units comprising a peptide sequence C_y-Y-G-F-X-W-G-Z-C_yy, or a pharmaceutically or physiologically acceptable salt thereof. The invention further relates to tumor targeting agents comprising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit. The present invention further relates to diagnostic or pharmaceutical compositions comprising at least one targeting unit or at least one targeting agent according to the present invention, and to the use of targeting units or targeting agents according to the present invention for the preparation of a medicament for the treatment of cancer or cancer related diseases, especially for the treatment of colon/colorectal cancer or its metastases.
  [FR] La présente invention concerne des unités de ciblage de tumeurs comprenant une séquence peptide C _y - Y - G - F - X - W - G - Z - C_yy, ou un sel pharmaceutiquement ou physiologiquement acceptable de celle-ci. L'invention concerne en outre des agents de ciblage de tumeurs comprenant au moins une unité de ciblage selon la présente invention, couplée directement ou indirectement à au moins une unité effectrice. La présente invention a pour objet en outre des compositions diagnostiques ou pharmaceutiques qui comprennent au moins une unité de ciblage ou au moins un agent de ciblage selon la présente invention, et d'utiliser des unités de ciblage ou des agents de ciblage selon la présente invention pour la préparation d'un médicament pour le traitement de cancer ou de maladies cancéreuses, en particulier pour le traitement de cancer du colon/du cancer colorectal ou de leurs métastases.